drugset / Trial / NCT03275103
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
Timeline
- Start
- 2017-09-19
- Primary completion
- 2026-01-07
- Completion
- 2026-01-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cevostamab | Monoclonal antibody | — | Intravenous |
| Background | Tocilizumab | Monoclonal antibody | — | Intravenous |